Celldex Therapeutics logo
Celldex Therapeutics
CLDX | NASDAQ
Chart Builder DCF Calculator
$28.59
-$0.24 (-0.83%)
At close: Nov 16, 2026, 4:00 PM ET
$29.00
+$0.41 (+1.43%)
After-hours: Nov 16, 2026, 7:30 PM ET

Celldex Therapeutics Company Profile

Company profile explained

Company Profile

Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Key Executives

Name Position
Anthony S. Marucci Founder, President, Chief Executive Officer & Director
Sam Martin Senior Vice President, Chief Financial Officer, Secretary & Treasurer
Diane C. Young Senior Vice President & Chief Medical Officer
Elizabeth Crowley Chief Product Development Officer & Senior Vice President
Freddy A. Jimenez Senior Vice President & General Counsel
Joseph Schlessinger Co-Founder & Member of Scientific Advisory Board
Margo Heath-Chiozzi Senior Vice President of Regulatory Affairs
Ronald A. Pepin Chief Business Officer & Senior Vice President
Sarah Cavanaugh Senior Vice President of Corporate Affairs & Administration
Tibor Keler Founder, Chief Scientific Officer & Executive Vice President

Latest SEC Filings

Date Type Title
Oct 07, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 22, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Jul 15, 2026 8-K Current Report
Jun 29, 2026 4 Filing
Jun 29, 2026 4 Filing
Jun 29, 2026 4 Filing
View All SEC Filings ➞
Celldex Therapeutics
Celldex Therapeutics logo
Country United States
IPO Date May 15, 1986
Industry Biotechnology
Sector Healthcare
Employees 198
CEO Anthony S. Marucci

Contact Details

Perryville III Building Hampton, New Jersey 08827 United States

Stock Details

Ticker Symbol CLDX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000744218
CUSIP Number 15117B202
ISIN Number US15117B2025
SIC Code 2835

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.